The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Reovirus Therapy of Tumors with Activated Ras Pathway
Abstract
Human reovirus requires an activated Ras signaling pathway for infection of cultured cells. To investigate whether this property can be exploited for cancer therapy, severe combined immune deficient mice bearing tumors established from v- erbB –transformed murine NIH 3T3 cells or human U87 glioblastoma cells were treated with the virus. A single intratumoral injection of virus resulted in regression of tumors in 65 to 80 percent of the mice. Treatment of immune-competent C3H mice bearing tumors established from ras -transformed C3H-10T1/2 cells also resulted in tumor regression, although a series of injections were required. These results suggest that, with further work, reovirus may have applicability in the treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., & Schlessinger, J. (1985) · Nature · doi:10.1038/313144a0 · Cited by 1,503
Heise, C., Sampson-Johannes, A., Williams, A., Mccormick, F., Von Hoff, D. D., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 940
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X. D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936
Wong, A. J., Bigner, S. H., Bigner, D. D., Kinzler, K. W., Hamilton, S. R., & Vogelstein, B. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.19.6899 · Cited by 849
Hermanson, M., Funa, N. S., Hartman, M., Claesson, L., Heldin, C., Westermark, B., & Nistér, M. (1992) · PubMed · Cited by 705
Ekstrand, A. J., Sugawa, N., James, C. D., & Collins, V. P. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4309 · Cited by 602
Cited by
Ras oncogenes: split personalities
Karnoub, A. E., & Weinberg, R. A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2438 · Cited by 1,467
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
Self-citationRoulston, A., Marcellus, R. C., & Branton, P. E. (1999) · Annual Review of Microbiology · doi:10.1146/annurev.micro.53.1.577 · Cited by 749
The interferon response circuit: Induction and suppression by pathogenic viruses
Haller, O., Kochs, G., & Weber, F. (2006) · Virology · doi:10.1016/j.virol.2005.09.024 · Cited by 681
Oncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Host defense, viruses and apoptosis
Barber, G. N. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400823 · Cited by 582
Kirn, D., Martuza, R. L., & Zwiebel, J. (2001) · Nature Medicine · doi:10.1038/89901 · Cited by 502
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Metabolism, Cell Surface Organization, and Disease
Dennis, J. W., Nabi, I. R., & Demetriou, M. (2009) · Cell · doi:10.1016/j.cell.2009.12.008 · Cited by 450
The dark side of Ras: regulation of apoptosis
Cox, A. D., & Der, C. J. (2003) · Oncogene · doi:10.1038/sj.onc.1207111 · Cited by 437
Replicative adenoviruses for cancer therapy
Alemany, R., Balagué, C., & Curiel, D. T. (2000) · Nature Biotechnology · doi:10.1038/77283 · Cited by 421
Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer
Kirn, D. H., & Thorne, S. H. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2545 · Cited by 402
The sweet spot: defining virus–sialic acid interactions
Stencel-Baerenwald, J. E., Reiss, K., Reiter, D. M., Stehle, T., & Dermody, T. S. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3346 · Cited by 382
Thomas, S., Izard, J., Walsh, E., Batich, K., Chongsathidkiet, P., Clarke, G., Sela, D. A., Muller, A. J., Mullin, J. M., Albert, K., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2929 · Cited by 367
Intergeneric poliovirus recombinants for the treatment of malignant glioma
Gromeier, M., Lachmann, S., Rosenfeld, M. R., Gutin, P. H., & Wimmer, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6803 · Cited by 363
Influenza Virus NS1 Protein Counteracts PKR-Mediated Inhibition of Replication
Bergmann, M., Garcia-Sastre, A., Carnero, E., Pehamberger, H., Wolff, K., Palese, P., & Muster, T. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6203-6206.2000 · Cited by 362
Kirn, D. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301377 · Cited by 349
Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339
Oncolytic viruses in cancer therapy
Vähä-Koskela, M. J. V., Heikkilä, J. E., & Hinkkanen, A. E. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.02.002 · Cited by 333
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
Bommareddy, P. K., Patel, A., Hossain, S., & Kaufman, H. L. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0238-9 · Cited by 322
High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus
Anderson, B. D., Nakamura, T., Russell, S. J., & Peng, K.-W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0884 · Cited by 315
Antonio Chiocca, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc948 · Cited by 306
Parato, K. A., Breitbach, C. J., Le Boeuf, F., Wang, J., Storbeck, C., Ilkow, C., Diallo, J.-S., Falls, T., Burns, J., Garcia, V., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.276 · Cited by 305
Oncolytic viral therapies – the clinical experience
Aghi, M., & Martuza, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1209037 · Cited by 288
Forsyth, P., Roldán, G., George, D., Wallace, C., Palmer, C. A., Morris, D., Cairncross, G., Matthews, M. V., Markert, J., Gillespie, Y., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300403 · Cited by 278
Self-citationOncolytic Viruses and the Immune System: The Dynamic Duo
Lemos de Matos, A., Franco, L. S., & McFadden, G. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.01.001 · Cited by 269
Oncolytic herpes simplex virus vectors for cancer virotherapy
Varghese, S., & Rabkin, S. D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700537 · Cited by 264
A Plasmid-Based Reverse Genetics System for Animal Double-Stranded RNA Viruses
Kobayashi, T., Antar, A. A. R., Boehme, K. W., Danthi, P., Eby, E. A., Guglielmi, K. M., Holm, G. H., Johnson, E. M., Maginnis, M. S., Naik, S., et al. (2007) · Cell Host & Microbe · doi:10.1016/j.chom.2007.03.003 · Cited by 263
Intravascular adenoviral agents in cancer patients: Lessons from clinical trials
Reid, T., Warren, R., & Kirn, D. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700539 · Cited by 258
Trial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Mahalingam, D., Fountzilas, C., Moseley, J., Noronha, N., Tran, H., Chakrabarty, R., Selvaggi, G., Coffey, M., Thompson, B., & Sarantopoulos, J. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3260-6 · Cited by 94
Self-citationImmunotherapy Resistance in Glioblastoma
Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34
Metadata
- Authors
- Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K.
- Venue
- Science
- Published
- 1998-11-13
- Volume
- 282
- Issue
- 5392
- Pages
- 1332-1334
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2090599158
- Cited by
- 750
- References
- 24
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.